History
Fearless of change JW Shinyak walks continuously.
Taking a strong step towards the clinical-to-field 10, we practice the founding principle of " pioneering spirit. "
2021
- ∙ Concluded an agreement for the joint research for anti-cancer immune cell therapy 'CAR-M' with Oncoinsight
2020
- ∙ Obtainment of the patent registrations for the manufacturing technology of anticancer / autoimmune disease dendritic cell therapy products both in Europe and China
2019
- ∙ Registered patent for dendritic cell therapy manufacturing technology in USA and Japan
2018
- ∙ Japanese patent registration for dendritic cell manufacturing method with increased specific gene expression
2017
- ∙ CreaVax- BC to Approve Clinical 1/2 Phase IND
2016
- ∙ Change Your Mission to JW Shinyak Company
2015
- ∙ Vision 70 + 5 Announcement
2014
- ∙ CreaVax-EMC, Clinical Phase 3 IND Approved
2013
- ∙ CreaVax-RA approves clinical 2b
2012
- ∙ Begin Hyangtonsitokain Project
2011
- ∙ Change Your Mission to JW Global Shinyak Company
- ∙ Group New CI Pre-Form
2009
- ∙ Combined New Stock KOSDAQ listing
2008
- ∙ The Head Office : Daeryoung Technotown, 664 Sasan-dong, Geumcheon-gu, Seoul, 3rd floor
2007
- ∙ Obtain item approval (CreaVax-SIC) and manufacturing license / KGMP
2005
- ∙ Mutual to internal and external shinyak
- ∙ Head Office : 345-30 Ace Line 3, Sasan-dong, Geumcheon-gu, Seoul
2001
- ∙ A large oil absorption merger
- ∙ Obtain approval for medical wholesale business (Pyeongtaek Plant)
2000
- ∙ Purchase a license to manufacture cosmetics (Pyeongtaek Plant)
1996
- ∙ Purchase a license to manufacture cosmetics (Pyeongtaek Plant)
- ∙ KGMP qualification certification (Pyeongtaek Plant)
1995
- ∙ Head Office : 330-11, Sinjeong-dong, Yangcheon-gu, Seoul
- ∙ Factory relocation : 441-8, Mogok-dong, Pyeongtaek, Gyeonggi-do
1991
- ∙ Mutual to Deayou Shinyak, Ltd.
1990
- ∙ The acquisition of the company's regular pharmaceutical company from internal and external constraints.